National

DCGI approves India's first qHPV vaccine to treat cervical cancer

Published on 14 Jul 2022

← Back to Current Affairs
  • Drugs Controller General of India (DCGI) granted market authorisation to Serum Institute of India (SII) to manufacture indigenously-developed India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer.
  • Cervical cancer is the second most frequent cancer among women between 15 and 44 years of age with a high death ratio in India.
  • The approval by the drug regulator of SII’s anti-cancer vaccine followed recommendation by the Subject Expert Committee (SEC) on COVID-19 of the CDSCO on June 15.
  • Earlier the Serum Institute had applied to the DCGI seeking market authorisation of the qHPV after the phase 2/3 clinical trial was completed with support of the Department of Biotechnology.

Discussion 0

No comments yet. Be the first to share your thoughts!

Join WhatsApp